Wellington Management Group LLP Has $13.25 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Wellington Management Group LLP cut its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 17.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 644,763 shares of the company's stock after selling 137,011 shares during the period. Wellington Management Group LLP owned approximately 0.63% of Intellia Therapeutics worth $13,250,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. ARK Investment Management LLC boosted its position in shares of Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock worth $251,849,000 after purchasing an additional 659,651 shares during the period. State Street Corp grew its stake in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after buying an additional 780,754 shares in the last quarter. FMR LLC grew its stake in shares of Intellia Therapeutics by 5.0% in the third quarter. FMR LLC now owns 2,339,522 shares of the company's stock valued at $48,077,000 after buying an additional 111,104 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock valued at $51,494,000 after buying an additional 371,189 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after acquiring an additional 98,865 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on NTLA shares. The Goldman Sachs Group cut their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Robert W. Baird dropped their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Finally, Wells Fargo & Company lowered their price target on Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating on the stock in a report on Monday, November 18th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $54.94.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.20% of the stock is owned by insiders.

Intellia Therapeutics Price Performance

NASDAQ NTLA traded down $0.66 on Friday, hitting $12.90. 3,187,759 shares of the company were exchanged, compared to its average volume of 1,760,464. Intellia Therapeutics, Inc. has a twelve month low of $12.47 and a twelve month high of $34.87. The firm has a market capitalization of $1.31 billion, a P/E ratio of -2.37 and a beta of 1.76. The company's 50 day moving average price is $16.13 and its 200-day moving average price is $20.60.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The company's revenue for the quarter was down 24.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.38) EPS. As a group, equities analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.